TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition (Adv. Sci. 4/2026)

Advanced Science 2026 Open access

Read full text
Authors: Yanchen Zhang, Ende Wu, Weibin Liu, Ling Zeng, Neng Ling, Hongmei Wang, Zhixing Li, Shuang Yao, Tonghe Pan, Xuanwen Li, Yate Huang, Xiaojing Li
+5 more Yunhai Tu, Wentao Yan, Jianzhang Wu, Mao Ye, Wencan Wu
DOI: 10.1002/advs.73392
Cited by: 0

Abstract

An Allosteric Strategy for Thyroid Eye Disease This illustration depicts an aptamer (purple) binding to the target protein (white) at an allosteric site. This strategic binding induces a conformational change that acts as a shield, preventing pathogenic autoantibodies (red) from initiating the disease cascade, while leaving the protein's normal function intact. More details can be found in the Research Article by Jianzhang Wu, Mao Ye, Wencan Wu, and co-workers (DOI: 10.1002/advs.202505586).

Fields of Study & Subjects

Ophthalmology and Eye Disorders Advanced biosensing and bioanalysis techniques Myasthenia Gravis and Thymoma

Publication details

Journal / source
Advanced Science
Volume
13
Issue
4
Publication date
1 January 2026
Language
EN